Published on
May 1, 2025
GSK's Nucala delivers positive outcomes in published trial results
The FTSE 100 pharmaceuticals giant said the data supported ongoing regulatory submissions, with a decision from the US FDA expected by 7 May. It said the trial met its primary endpoint, showing a 21% reduction in the annualised rate of moderate-to-severe …
Source:
ShareCast
-
Neutral
